Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 62 of 1,261
  1. US 12226412

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  2. US 12227508

    TGF-Ξ² inhibitors

    Rigel Pharmaceuticals, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  3. US 12227503

    Compositions and methods for modulating hair growth

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  4. US 12227482

    Compounds and compositions for the treatment of cancer

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  5. US 12227504

    Spirocyclic compounds

    C4 THERAPEUTICS, INC. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  6. US 12226491

    Nano-satellite complexes

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  7. US 12226524

    Coated implants for long-term controlled release of antibody therapeutics

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  8. US 12226450

    Peptides and methods for treating disease

    The Regents of the University of Colorado, a Body Corporate Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  9. US 12227580

    Antigen binding molecules that bind LIGHT

    CENTESSA PHARMACEUTICALS (UK) LIMITED Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  10. US 12227740

    CBLB endonuclease variants, compositions, and methods of use

    REGENERON PHARMACEUTICALS, INC. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  11. US 12227581

    Anti-BCMA single domain antibodies and application thereof

    SHENZHEN PREGENE BIOPHARMA CO., LTD. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  12. US 12227562

    Compositions and methods to treat viral infection and co-morbidities

    The Regents of the University of California Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  13. US 12230379

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  14. US 12227584

    Multivalent and multispecific OX40-binding fusion proteins

    Inhibrx Biosciences, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  15. US 12226490

    Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class

    Sutro Biopharma, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  16. US 12227744

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  17. US 2025049789

    METHODS OF TREATING ALOPECIA ARAETA

    ABBVIE INC [US] Β· Granted Feb 13, 2025 Β· Expires Feb 8, 2045

    granted
  18. US 12221607

    Multi-targeted single entity conjugates

    Alnylam Pharmaceuticals, Inc. Β· Granted Feb 11, 2025 Β· Expires Feb 6, 2045

    granted
  19. US 12221463

    Method of promoting wound healing by inhibiting CCR3

    The Board of Regents of the University of Oklahoma Β· Granted Feb 11, 2025 Β· Expires Feb 6, 2045

    granted
  20. US 12220389

    Combination therapy for the treatment of tinnitus and other medical conditions

    The Regents of the University of California Β· Granted Feb 11, 2025 Β· Expires Feb 6, 2045

    granted
  21. US 12223643

    Machine-learning system for diagnosing disorders and diseases and determining drug responsiveness

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Feb 11, 2025 Β· Expires Feb 6, 2045

    granted
  22. US 12222355

    Therapeutic antibodies against ROR-1 protein and methods for use of same

    The Regents of the University of California Β· Granted Feb 11, 2025 Β· Expires Feb 6, 2045

    granted
  23. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. Β· Granted Feb 11, 2025 Β· Expires Feb 6, 2045

    granted
  24. US 12220453

    Compositions and treatments for Haemophilus influenzae

    The Board of Regents of the University of Oklahoma Β· Granted Feb 11, 2025 Β· Expires Feb 6, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.